Astragalus for General immunity and Astragalus
Each entry’s own grades, side by side. A grade says how strong the evidence is for one outcome — it does not rank one entry over the other.
Evidence brief
Astragalus for General immunity
Evidence grade C — Weak
Grade C1 graded outcomerevised Jul 10, 2026
Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.
Compound or practice
Astragalus
A traditional immune tonic with adjunct-in-chemo and kidney-protection signals — thin standalone evidence.
Grade C2 graded outcomesrevised Jul 10, 2026
A structured monograph in Prometheus's bundled library. Its grades are the monograph's own reading of the evidence, not a peer-reviewed review.
Graded in both
Outcomes are matched by name. Two entries can describe the same outcome in different words, so one listed further down may still be graded in the other.
| Outcome | Astragalus for General immunity | Astragalus |
|---|---|---|
| General immunity | Evidence grade CSmall effectlowWeak | Evidence grade CSmall effectlowWeak |
Graded only in Astragalus for General immunity
None — every outcome it grades is graded in both.
Graded only in Astragalus
- Chemotherapy side effects (adjunct) Small effectEvidence grade C
What each entry says about the other
- Astragalus for General immunity’s entry · Goes with: Read the full Astragalus monograph
Both columns are read from the entries as they stand in this library. A comparison is not advice to take either one, and it is no substitute for a clinician who knows the person.